The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
An overview of triple-negative breast cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 3×
“In contrast, more than 50 % ER-positive breast cancers recur between 5 and 10 years after surgery, and in the long term more events will occur in high-grade ER-positive breast cancers as compared to TNBC [6, 55, 74, 75].”
BackgroundCortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Metastatic Behavior of Breast Cancer Subtypes
Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,067
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967 · cited 1×
“The authors concluded that future attempts to dissect the biology and therapeutic responses of TNBC require the determination of individual tumor clonal genotypes [54].”
BackgroundBreast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789 · cited 1×
“Various studies of neoadjuvant chemotherapy in TNBC confirmed that pCR can be used as a surrogate marker for long-term response and survival [108].”
BackgroundGene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Prognostic markers in triple‐negative breast cancer
Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F., & Ellis, I. O. (2007) · Cancer · doi:10.1002/cncr.22381 · Cited by 1,283
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
Voduc, K. D., Cheang, M. C. U., Tyldesley, S., Gelmon, K., Nielsen, T. O., & Kennecke, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9284 · Cited by 1,243
Ki67 in breast cancer: prognostic and predictive potential
Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70262-1 · Cited by 1,207
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Basal-Like Breast Cancer: A Critical Review
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1748 · Cited by 1,164
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094 · cited 1×
“The majority (74 %) of patients enrolled in the trial were HER2 negative and 19 % had TNBC [134].”
BackgroundRobert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Epidemiology of basal-like breast cancer
Millikan, R. C., Newman, B., Tse, C.-K., Moorman, P. G., Conway, K., Smith, L. V., Labbok, M. H., Geradts, J., Bensen, J. T., Jackson, S., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9632-6 · Cited by 886
Triple negative tumours: a critical review
Reis‐Filho, J. S., & Tutt, A. N. J. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02889.x · Cited by 884
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Lakhani, S. R., van de Vijver, M. J., Jacquemier, J., Anderson, T. J., Osin, P. P., McGuffog, L., & Easton, D. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.023 · Cited by 823
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Subtypes of Breast Cancer Show Preferential Site of Relapse
Smid, M., Wang, Y., Zhang, Y., Sieuwerts, A. M., Yu, J., Klijn, J. G. M., Foekens, J. A., & Martens, J. W. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5644 · Cited by 813
Smith, L. A., Cornelius, V. R., Plummer, C. J., Levitt, G., Verrill, M., Canney, P., & Jones, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-337 · Cited by 753
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1658 · Cited by 731
Yang, X. R., Chang-Claude, J., Goode, E. L., Couch, F. J., Nevanlinna, H., Milne, R. L., Gaudet, M., Schmidt, M. K., Broeks, A., Cox, A., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq526 · Cited by 691
Plasma Sex Steroid Hormone Levels and Risk of Breast Cancer in Postmenopausal Women
Hankinson, S. E., Willett, W. C., Manson, J. E., Colditz, G. A., Hunter, D. J., Spiegelman, D., Barbieri, R. L., & Speizer, F. E. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.17.1292 · Cited by 687
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1414 · Cited by 672
Fisher, B., Brown, A. M., Dimitrov, N. V., Poisson, R., Redmond, C., Margolese, R. G., Bowman, D., Wolmark, N., Wickerham, D. L., & Kardinal, C. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1483 · Cited by 620
Atchley, D. P., Albarracin, C. T., Lopez, A., Valero, V., Amos, C. I., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Arun, B. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6231 · Cited by 604
Roché, H., Fumoleau, P., Spielmann, M., Canon, J.-L., Delozier, T., Serin, D., Symann, M., Kerbrat, P., Soulié, P., Eichler, F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3916 · Cited by 577
Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S., Stemke-Hale, K., Hennessy, B. T., Arun, B. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 573
Kyndi, M., Sørensen, F. B., Knudsen, H., Overgaard, M., Nielsen, H. M., & Overgaard, J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5565 · Cited by 568
van de Rijn, M., Perou, C. M., Tibshirani, R., Haas, P., Kallioniemi, O., Kononen, J., Torhorst, J., Sauter, G., Zuber, M., Köchli, O. R., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64476-8 · Cited by 560
Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., Mierzwa, T., Szwiec, M., Wiśniowski, R., Siolek, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7019 · Cited by 516
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini, K. S., Viale, G., Loi, S., Bradbury, I., Bliss, J. M., Azim, H. A., Ellis, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2010 · Cited by 465
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Robidoux, A., Atkins, J. N., Baez-Diaz, L., Brufsky, A. M., Mehta, R. S., Fehrenbacher, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111097 · Cited by 461
How basal are triple‐negative breast cancers?
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23518 · Cited by 443
Amir, E., Miller, N., Geddie, W., Freedman, O., Kassam, F., Simmons, C., Oldfield, M., Dranitsaris, G., Tomlinson, G., Laupacis, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5232 · Cited by 434 · cited 2×
“Although receptor status switch between the primary breast tumor and the metastatic lesion has been reported for ER, PR and HER2, only a few patients with TNBC will gain extra treatment options [132].”
BackgroundCameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., Steger, G. G., Suter, T. M., Toi, M., Parmar, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70335-8 · Cited by 432
De Laurentiis, M., Cancello, G., D'Agostino, D., Giuliano, M., Giordano, A., Montagna, E., Lauria, R., Forestieri, V., Esposito, A., Silvestro, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3787 · Cited by 416
Autier, P., Boniol, M., LaVecchia, C., Vatten, L., Gavin, A., Hery, C., & Heanue, M. (2010) · BMJ · doi:10.1136/bmj.c3620 · Cited by 412
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
Baselga, J., Albanell, J., Ruiz, A., Lluch, A., Gascón, P., Guillém, V., González, S., Sauleda, S., Marimón, I., Tabernero, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.326 · Cited by 411
Finn, R. S., Dering, J., Ginther, C., Wilson, C. A., Glaspy, P., Tchekmedyian, N., & Slamon, D. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9463-x · Cited by 409
Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
Peters, A. A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M. M., Harris, J. M., Jindal, S., Segara, D., Jia, L., Moore, N. L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0452 · Cited by 405
Press, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J.-Y., & Bernstein, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.094 · Cited by 391
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Horiuchi, D., Kusdra, L., Huskey, N. E., Chandriani, S., Lenburg, M. E., Gonzalez-Angulo, A. M., Creasman, K. J., Bazarov, A. V., Smyth, J. W., Davis, S. E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111512 · Cited by 378
Current issues in ER and HER2 testing by IHC in breast cancer
Gown, A. M. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.34 · Cited by 374
Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363
Schneider, B. P., & Miller, K. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.017 · Cited by 350
Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents
Isakoff, S. J. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181d24ff7 · Cited by 348
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348
Abdulkarim, B. S., Cuartero, J., Hanson, J., Deschênes, J., Lesniak, D., & Sabri, S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4714 · Cited by 345
Triple-Negative Breast Cancer: Correlation between MR Imaging and Pathologic Findings
Uematsu, T., Kasami, M., & Yuen, S. (2009) · Radiology · doi:10.1148/radiol.2503081054 · Cited by 344
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Gronwald, J., Zuziak, D., Cybulski, C., Kladny, J., Gorski, B., Lubinski, J., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0128-9 · Cited by 340
NCCN breast cancer clinical practice guidelines in oncology: an update.
Carlson, R. W. (2003) · PubMed · Cited by 329
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Fasching, P. A., Heusinger, K., Haeberle, L., Niklos, M., Hein, A., Bayer, C. M., Rauh, C., Schulz-Wendtland, R., Bani, M. R., Schrauder, M., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-486 · Cited by 328
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors
Kwan, M. L., Kushi, L. H., Weltzien, E., Maring, B., Kutner, S. E., Fulton, R. S., Lee, M. M., Ambrosone, C. B., & Caan, B. J. (2009) · Breast Cancer Research · doi:10.1186/bcr2261 · Cited by 318
Tan, D. S. P., Marchió, C., Jones, R. L., Savage, K., Smith, I. E., Dowsett, M., & Reis-Filho, J. S. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9756-8 · Cited by 318
Rakha, E., Putti, T., Abd El‐Rehim, D., Paish, C., Green, A., Powe, D., Lee, A., Robertson, J., & Ellis, I. (2006) · The Journal of Pathology · doi:10.1002/path.1916 · Cited by 311
Huober, J., von Minckwitz, G., Denkert, C., Tesch, H., Weiss, E., Zahm, D. M., Belau, A., Khandan, F., Hauschild, M., Thomssen, C., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1103-9 · Cited by 292
von Minckwitz, G., Untch, M., Nüesch, E., Loibl, S., Kaufmann, M., Kümmel, S., Fasching, P. A., Eiermann, W., Blohmer, J.-U., Costa, S. D., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1228-x · Cited by 280
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2008) · The Lancet · doi:10.1016/s0140-6736(08)60069-0 · Cited by 279
Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years
Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D. R., Porter, P. L., & Malone, K. E. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-1005 · Cited by 271
Dowsett, M., Cuzick, J., Wale, C., Howell, T., Houghton, J., & Baum, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4829 · Cited by 260
Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3033 · Cited by 258
Multigene prognostic tests in breast cancer: past, present, future
Győrffy, B., Hatzis, C., Sanft, T., Hofstatter, E., Aktas, B., & Pusztai, L. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0514-2 · Cited by 257
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Cardoso, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr371 · Cited by 256
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
Straver, M. E., Glas, A. M., Hannemann, J., Wesseling, J., van de Vijver, M. J., Rutgers, E. J. T., Vrancken Peeters, M.-J. T. F. D., van Tinteren, H., van‘t Veer, L. J., & Rodenhuis, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0333-1 · Cited by 252
Basu, S., Chen, W., Tchou, J., Mavi, A., Cermik, T., Czerniecki, B., Schnall, M., & Alavi, A. (2008) · Cancer · doi:10.1002/cncr.23226 · Cited by 248
Reproductive History and Oral Contraceptive Use in Relation to Risk of Triple-Negative Breast Cancer
Phipps, A. I., Chlebowski, R. T., Prentice, R., McTiernan, A., Wactawski-Wende, J., Kuller, L. H., Adams-Campbell, L. L., Lane, D., Stefanick, M. L., Vitolins, M., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr030 · Cited by 248
Stark, A., Kleer, C. G., Martin, I., Awuah, B., Nsiah‐Asare, A., Takyi, V., Braman, M., E. Quayson, S., Zarbo, R., Wicha, M., et al. (2010) · Cancer · doi:10.1002/cncr.25276 · Cited by 236
Bianchini, G., Qi, Y., Alvarez, R. H., Iwamoto, T., Coutant, C., Ibrahim, N. K., Valero, V., Cristofanilli, M., Green, M. C., Radvanyi, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2419 · Cited by 228
Panet-Raymond, V., Gottlieb, B., Beitel, L. K., Pinsky, L., & Trifiro, M. A. (2000) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(00)00279-3 · Cited by 202
Triple-negative breast cancer: correlation between imaging and pathological findings
Ko, E. S., Lee, B. H., Kim, H.-A., Noh, W.-C., Kim, M. S., & Lee, S.-A. (2010) · European Radiology · doi:10.1007/s00330-009-1656-3 · Cited by 194
Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance
Rakha, E. A., El-Rehim, D. A., Paish, C., Green, A. R., Lee, A. H. S., Robertson, J. F., Blamey, R. W., Macmillan, D., & Ellis, I. O. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.08.015 · Cited by 193
Ogawa, Y., Hai, E., Matsumoto, K., Ikeda, K., Tokunaga, S., Nagahara, H., Sakurai, K., Inoue, T., & Nishiguchi, Y. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0770-6 · Cited by 184
Imaging of triple-negative breast cancer
Dogan, B. E., & Turnbull, L. W. (2012) · Annals of Oncology · doi:10.1093/annonc/mds191 · Cited by 182
Update on triple-negative breast cancer: prognosis and management strategies
Neven, P., Brouckaert, Wildiers, & Floris, G. (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s18541 · Cited by 176
Triple-Negative Breast Cancer and the Need for New Therapeutic Targets
Engebraaten, O., Vollan, H. K. M., & Børresen-Dale, A.-L. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.05.033 · Cited by 175
Breast Cancer Adjuvant Therapy: Time to Consider Its Time-Dependent Effects
Jatoi, I., Anderson, W. F., Jeong, J.-H., & Redmond, C. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3550 · Cited by 172
Stagg, J., & Allard, B. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012475152 · Cited by 166
Azoulay, S., Laé, M., Fréneaux, P., Merle, S., Al Ghuzlan, A., Chnecker, C., Rosty, C., Klijanienko, J., Sigal-Zafrani, B., Salmon, R., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800483 · Cited by 163
Ladoire, S., Bonnetain, F., Gauthier, M., Zanetta, S., Petit, J. M., Guiu, S., Kermarrec, I., Mourey, E., Michel, F., Krause, D., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0227 · Cited by 162
Purrington, K. S., Slager, S., Eccles, D., Yannoukakos, D., Fasching, P. A., Miron, P., Carpenter, J., Chang-Claude, J., Martin, N. G., Montgomery, G. W., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgt404 · Cited by 161
Gerber, B., Loibl, S., Eidtmann, H., Rezai, M., Fasching, P. A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., Hanusch, C. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt361 · Cited by 161
Jagsi, R., Raad, R. A., Goldberg, S. I., Sullivan, T., Michaelson, J. S., Powell, S. N., & Taghian, A. G. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.12.014 · Cited by 158
Yang, W. T., Dryden, M. J., Broglio, K. R., Gilcrease, M. Z., Dawood, S. S., Dempsey, P. J., Valero, V., Hortobágyi, G. N., Atchley, D. P., & Arun, B. K. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9810-6 · Cited by 157
Wang, Y., Ikeda, D. M., Narasimhan, B., Longacre, T. A., Bleicher, R. J., Pal, S., Jackman, R. J., & Jeffrey, S. S. (2008) · Radiology · doi:10.1148/radiol.2462070169 · Cited by 157
Triple-Negative Breast Cancer and Obesity in a Rural Appalachian Population
Vona-Davis, L. C., Rose, D. P., Hazard-Jenkins, H. W., Howard-McNatt, M. M., Adkins, F. C., Partin, J. F., & Hobbs, G. R. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0544 · Cited by 154
Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome
Montagna, E., Maisonneuve, P., Rotmensz, N., Cancello, G., Iorfida, M., Balduzzi, A., Galimberti, V. E., Veronesi, P., Luini, A., Pruneri, G., et al. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2012.09.002 · Cited by 148
The association of metabolic syndrome with triple-negative breast cancer
Maiti, B., Kundranda, M. N., Spiro, T. P., & Daw, H. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0591-y · Cited by 147
Directed Therapy of Subtypes of Triple-Negative Breast Cancer
Carey, L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-71 · Cited by 142
Brufsky, A., Valero, V., Tiangco, B., Dakhil, S. R., Brize, A., Rugo, H. S., Rivera, R., Duenne, A., Bousfoul, N., & Yardley, D. A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2008-6 · Cited by 137
Src: a potential target for the treatment of triple-negative breast cancer
Tryfonopoulos, D. J., Walsh, S., Collins, D. M., Flanagan, L., Quinn, C., Corkery, B., McDermott, E. W. M., Evoy, D., Pierce, A., O’Donovan, N., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq757 · Cited by 137
Dickler, M. N., Rugo, H. S., Eberle, C. A., Brogi, E., Caravelli, J. F., Panageas, K. S., Boyd, J. A., Yeh, B. M., Lake, D. E., Dang, C. T., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0141 · Cited by 127
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations
Bayraktar, S., Gutierrez‐Barrera, A. M., Liu, D., Tasbas, T., Akar, U., Litton, J. K., Lin, E., Albarracin, C. T., Meric‐Bernstam, F., Gonzalez-Angulo, A. M., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1711-z · Cited by 123
Adjuvant treatments for triple-negative breast cancers
Joensuu, H., & Gligorov, J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds194 · Cited by 121
Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer
Purrington, K. S., Vachon, C. M., Lee, A. M., Slager, S., Lesnick, T. G., Olswold, C., Fasching, P. A., Miron, P. L., Eccles, D., Carpenter, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1266 · Cited by 119
Jeong, H., Ryu, Y.-J., An, J., Lee, Y., & Kim, A. (2012) · Histopathology · doi:10.1111/j.1365-2559.2012.04195.x · Cited by 116
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
Baselga, J. M., Zambetti, M., Llombart‐Cussac, A., Manikhas, G., Kubista, E., Steger, G. G., Makhson, A. N., Tjulandin, S., Ludwig, H., Verrill, M. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2646 · Cited by 113
Chang, H. R., Glaspy, J. A., Allison, M. A., Kass, F. C., Elashoff, R. M., Chung, D. U., & GORNBEIN, J. A. (2010) · Cancer · doi:10.1002/cncr.25309 · Cited by 111
Chen, X. S., Nie, X.-Y., Chen, C. M., Wu, J., Wu, J., Lu, J., Shao, Z., Shen, Z., & Shen, K. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq041 · Cited by 108
Sikov, W. M., Dizon, D. S., Strenger, R., Legare, R. D., Theall, K. P., Graves, T. A., Gass, J. S., Kennedy, T. A., & Fenton, M. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4163 · Cited by 108
Søreide, J. A., Lea, O. A., Varhaug, J. E., Skarstein, A., & Kvinnsland, S. (1992) · PubMed · Cited by 105
Truong, P. T., Lesperance, M., Culhaci, A., Kader, H. A., Speers, C. H., & Olivotto, I. A. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.09.013 · Cited by 105
19p13.1 Is a Triple-Negative–Specific Breast Cancer Susceptibility Locus
Stevens, K. N., Fredericksen, Z., Vachon, C. M., Wang, X., Margolin, S., Lindblom, A., Nevanlinna, H. A., Greco, D., Aittomäki, K., BLOMQVIST, C. P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3364 · Cited by 105
Gluz, O., Nitz, U. A., Harbeck, N., Ting, E., Kates, R. E., Herr, A., Lindemann, W., Jackisch, C., Berdel, W. E., Kirchner, H. H., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm551 · Cited by 103
Gelmon, K. A., Hirte, H. W., Robidoux, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3002 · Cited by 103
Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues
Recchione, C., Venturelli, E., Manzari, A., Cavalleri, A., Martinetti, A., & Secreto, G. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00017-t · Cited by 101
Kabat, G. C., Kim, M., Phipps, A. I., Li, C. I., Messina, C. R., Wactawski‐Wende, J., Kuller, L. H., Simon, M. S., Yasmeen, S., Wassertheil-Smoller, S. W., et al. (2011) · Cancer Causes & Control · doi:10.1007/s10552-011-9750-7 · Cited by 99
TNT Trial TMG, B. (., Robertson, L. B., Hanson, H., Seal, S., Warren-Perry, M., Hughes, D., Howell, I., Turnbull, C., Houlston, R. S., Shanley, S., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.31 · Cited by 97
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer
Perez, E. A., Patel, T., & Moreno‐Aspitia, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0824-0 · Cited by 90
Lerma, E., Peiró, G., y Cajal, T. R., Fernandez, S., Martínez, D., Pons, C., Muñoz, F., Sabaté, J. M., Alonso, C., Ojeda, B., et al. (2007) · Modern Pathology · doi:10.1038/modpathol.3800961 · Cited by 88
Panoff, J., Hurley, J. E., Takita, C., dos Reis, I. M., Zhao, W. K., Sujoy, V., Gomez, C. R., Jordà, M., Koniaris, L. G., & Wright, J. L. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1495-1 · Cited by 88
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer
Evans, D. G., Howell, A., Ward, D., Lalloo, F. I., Jones, J. L., & Eccles, D. (2011) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100006 · Cited by 87
5α‐Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production
Suzuki, T., Miki, Y., Moriya, T., Akahira, J., Ishida, T., Hirakawa, H., Yamaguchi, Y., Hayashi, S., & Sasano, H. (2006) · International Journal of Cancer · doi:10.1002/ijc.22317 · Cited by 86
Insulin resistance, obesity and breast cancer risk
Pichard, C., Plu‐Bureau, G., Castro, M. N.-E., & Gompel, A. (2008) · Maturitas · doi:10.1016/j.maturitas.2008.03.002 · Cited by 82
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Robidoux, A., Atkins, J. N., Báez-Díaz, L., Brufsky, A., Mehta, R. S., Fehrenbacher, L., et al. (2013) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3182877729 · Cited by 81
Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
Rivera, E., Lee, J., & Davies, A. M. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0143 · Cited by 79
Buchanan, G., Birrell, S. N., Peters, A. A., Bianco‐Miotto, T., Ramsay, K., Cops, E. J., Yang, M., Harris, J. M., Simila, H. A., Moore, N. L. T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3077 · Cited by 79
Straver, M. E., Aukema, T. S., Olmos, R. A. V., Rutgers, E. J. T., Gilhuijs, K. G. A., Schot, M. E., Vogel, W. V., & Peeters, M.-J. T. F. D. V. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1343-2 · Cited by 78
Breast cancer subtypes and outcome after local and regional relapse
Montagna, E., Bagnardi, V., Rotmensz, N., Viale, G., Renne, G., Cancello, G., Balduzzi, A., Scarano, E., Veronesi, P., Luini, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr129 · Cited by 78
Changing End Points in Breast-Cancer Drug Approval — The Avastin Story
D’Agostino, R. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1106984 · Cited by 77
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
Martín, M., Romero, A., Cheang, M. C. U., García‐Asenjo, J. A. L., García-Sáenz, J. Á., Oliva, B., Román, J. M. S. S., He, X., Casado, A., de la Torre, J., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1461-y · Cited by 73
Hall, R., Aspinall, J., Horsfall, D., Birrell, S., Bentel, J. M., Sutherland, R. L., & Tilley, W. D. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.513 · Cited by 71
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
Fornier, M. N., Morris, P. G., Abbruzzi, A., D’Andrea, G. M., Gilewski, T., Bromberg, J., Dang, C. T., Dickler, M. N., Modi, S., Seidman, A. D., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr018 · Cited by 66
Solin, L. J., Hwang, W., & Vapiwala, N. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.018 · Cited by 61
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Gronwald, J., Byrski, T., Huzarski, T., Dent, R. A., Bielicka, V., Zuziak, D., Wiśniowski, R., Lubiński, J., & Narod, S. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.502 · Cited by 61
Dutta, B., Pusztai, L., Qi, Y., André, F., Lazar, V., Bianchini, G., Ueno, N. T., Agarwal, R., Wang, B., Shiang, C. Y., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.584 · Cited by 54
New selective estrogen and androgen receptor modulators
Clarke, B. L., & Khosla, S. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32832ca447 · Cited by 54
Boyle, P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69225-8 · Cited by 51
Heusinger, K., Jud, S. M., Häberle, L., Hack, C. C., Adamietz, B. R., Meier-Meitinger, M., Lux, M. P., Wittenberg, T. C., Wagner, F., Loehberg, C. R., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27515 · Cited by 50
Oestrogen and androgen receptors in breast cancer and response to endocrine therapy.
Persijn, J.-P., Korsten, C. B., & Engelsman, E. (1975) · BMJ · doi:10.1136/bmj.4.5995.503 · Cited by 49
Triple Negative Breast Cancer - Our Experience and Review
Krishnamurthy, S., Poornima, R., Challa, V. R., & Goud, Y. G. B. (2012) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-012-0138-2 · Cited by 48
Nieto, Y. L., & Shpall, E. J. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328324f48b · Cited by 28
Locoregional treatments for triple-negative breast cancer
EIERMANN, W., & Vallis, K. A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds192 · Cited by 27
Byrne, M., Gebski, V., Forbes, J., Tattersall, M. H. N., Simes, R. J., Coates, A. S., Dewar, J. M., Lunn, M., Flower, C., Gill, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.9.3141 · Cited by 26
Schmidt, G., Meyberg-Solomayer, G., Gerlinger, C., Juhasz-Böss, I., Herr, D. J., Rody, A., Liedtke, C., & Solomayer, E. (2014) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3331-4 · Cited by 24
Response from the Cochrane Collaboration
Clarke, M. J., Tharyan, P., & Green, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60196-8 · Cited by 24
Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers?
Evans, D. G., & Howell, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1562 · Cited by 11
Bryan (1984) · doi:10.1002/1097-0142(19841201)54:11<2436::aid-cncr2820541121>3.0.co;2-h
Cited by
Epidemiology of breast cancer in Indian women: Breast cancer epidemiology
Malvia, S., Bagadi, S. A., Dubey, U. S., & Saxena, S. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12661 · Cited by 784
Molecular Subtypes and Local-Regional Control of Breast Cancer
Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.005 · Cited by 450
Sebastian, A., Hum, N. R., Martin, K. A., Gilmore, S. F., Peran, I., Byers, S. W., Wheeler, E. K., Coleman, M. A., & Loots, G. G. (2020) · Cancers · doi:10.3390/cancers12051307 · Cited by 260
Jusu, S. M., Obayemi, J. D., Salifu, A. A., Nwazojie, C. C., Uzonwanne, V., Odusanya, O. S., & Soboyejo, W. O. (2020) · Scientific Reports · doi:10.1038/s41598-020-71129-0 · Cited by 112
CAPER as a therapeutic target for triple negative breast cancer
Campbell, M. C., Pontiggia, L., Russell, A. Y., Schwarting, R., Camacho, J., Jasmin, J.-F., & Mercier, I. (2018) · Oncotarget · doi:10.18632/oncotarget.25719 · Cited by 10
Metadata
- Authors
- Kumar, P., & Aggarwal, R.
- Venue
- Archives of Gynecology and Obstetrics
- Published
- 2015-09-04
- Volume
- 293
- Issue
- 2
- Pages
- 247-269
- ISSN
- 0003-9128 (ISSN-L)
- 0932-0067
- 1432-0711
- OpenAlex
- W1256125786
- Cited by
- 771
- References
- 163
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.